Table 2. Number of isolates responsible for non-invasive pneumococcal pneumonia in adult patients (≥18 years), according to vaccine serotype groups and age groups, 2012–2015.
| Serotype Groupsb | No. isolates (%) | 2015 | CAa | |||
|---|---|---|---|---|---|---|
| 2012 | 2013 | 2014 | ||||
| 18–49 years | PCV7 | 12 (12.9) | 11 (16.4) | 8 (10.3) | 16 (15.8) | 0.782 |
| 1, 5 and 7F | 1 (1.1) | 1 (1.5) | 2 (2.6) | 1 (1.0) | 0.926 | |
| 3, 6A and 19A | 19 (20.4) | 11 (16.4) | 10 (12.8) | 20 (19.8) | 0.800 | |
| PCV13 | 32 (34.4) | 23 (34.3) | 20 (25.6) | 37 (36.6) | 0.983 | |
| addPPV23 | 25 (26.9) | 15 (22.4) | 28 (35.9) | 30 (29.7) | 0.417 | |
| NVTs | 36 (38.7) | 29 (43.3) | 30 (38.5) | 34 (33.7) | 0.385 | |
| 50–64 years | PCV7 | 12 (14.1) | 7 (8.4) | 7 (7.4) | 8 (6.7) | 0.328 |
| 1, 5 and 7F | 3 (3.5) | 0 (0) | 1 (1.1) | 1 (0.8) | 0.656 | |
| 3, 6A and 19A | 15 (17.6) | 23 (27.7) | 23 (24.2) | 19 (16.0) | 0.095 | |
| PCV13 | 30 (35.3) | 30 (36.1) | 31 (32.6) | 28 (23.5) | 0.026 | |
| PPV23 add | 45 (18.8) | 50 (27.7) | 53 (24.2) | 65 (32.8) | 0.082 | |
| NVTs | 39 (45.9) | 30 (36.1) | 41 (24.2) | 52 (32.8) | 0.531 | |
| ≥65 years | PCV7 | 26 (13.7) | 23 (13.6) | 17 (12.3) | 24 (1.1) | 0.381 |
| 1, 5 and 7F | 3 (1.6) | 3 (1.8) | 1 (0.7) | 4 (1.8) | 0.976 | |
| 3, 6A and 19A | 36 (18.9) | 36 (21.3) | 32 (23.2) | 37 (17.1) | 0.665 | |
| PCV13 | 65 (34.2) | 62 (36.7) | 50 (36.2) | 65 (30.0) | 0.332 | |
| PPV23 add | 50 (26.3) | 48 (28.4) | 27 (19.6) | 55 (25.3) | 0.078 | |
| NVTs | 75 (39.5) | 59 (34.9) | 61 (44.2) | 97 (44.7) | 0.125 | |
a CA, Cochran Armitage test of trend.
b PCV7, serotypes included in the 7-valent pneumococcal conjugate vaccine. PCV13, serotypes included in the 13-valent pneumococcal conjugate vaccine. addPPV23, the additional 11 serotypes present in the 23-valent pneumococcal polysaccharide vaccine but absent from PCV13. NVTs, serotypes not included in any of the currently available pneumococcal vaccines.